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ABSTRACT 
Background: Hereditary hemorrhagic telangiectasia is a dominantly inherited genetic 
vascular disorder in which epistaxis is the most frequent manifestation responsible for high 
morbidity. Management of this symptom has no standard and local treatments are often 
aggressive, their efficacy is variable and has not been proven. Antiangiogenic drugs, such as 
bevacizumab, are a new treatment strategy. Its systemic administration in patients with HHT 
improves liver damage-related symptoms and epistaxis. To limit the systemic adverse effects 
of bevacizumab and to ease administration, a local administration seems suitable.  
Primary objective: to evaluate the tolerance of increasing doses of bevacizumab 
administered as a nasal spray in patients with HHT-related epistaxis. Secondary objectives 
were to study bevacizumab bioavalability and efficacy against epistaxis when given as nasal 
spray. 
Methodology: Phase-1, randomized, double-blind, placebo-controlled, monocentric study 
carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group was made up 
of 6 verum and 2 placebos. Five increasing doses of bevacizumab nasal spray (25 mg/mL) 
were evaluated: 12.5, 25, 50, 75 and 100 mg.  
Results: A total of 41 patients were included between October 2011 and October 2012. 
Bevacizumab nasal spray was well tolerated in all patients and the drug was not detected in 
their serum. No dose limiting toxicity was observed. No efficacy was observed at any dose in 
this study. 
Conclusion: Based on these results, bevacizumab nasal spray is a safe treatment of epistaxis 
in HHT. However, a randomized phase 2 study is needed to determine its efficacy. 
Trial Registration: ClinicalTrials.gov Identifier #NCT01507480 
 
Words: 237 
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INTRODUCTION 
 Hereditary hemorrhagic telangiectasia (HHT) (OMIM#187300) is a dominantly 
inherited genetic vascular disorder characterized by recurrent epistaxis, cutaneous 
telangiectasia and visceral arteriovenous malformations (AVM) that affect many organs, 
including the lungs, gastrointestinal tract, liver and brain. Diagnosis is based on the Curaçao 
criteria and is considered definite if at least three of the four following criteria are fulfilled 1: 
1) spontaneous and recurrent epistaxis, 2) telangiectasia, 3) family history and 4) visceral 
lesions.  
The most apparent expression of the disorder is the occurrence of spontaneous, 
repeated epistaxis 2. These epistaxis can be severe and life threatening; they are often the 
cause of chronic anaemia, and can require continuous martial treatment and multiple 
transfusions. The handling of this major symptom is badly coded and often demands local 
treatments or medication whose efficacy is not sufficiently documented 3, 4.  
 Two genes are associated with HHT: ENG coding for endoglin5 and ACRLV1 coding 
for the activin receptor-like kinase 1, ALK-16. Mutations in either one of these two genes 
account for most clinical cases. In addition, mutations in MADH4 (encoding SMAD4), which 
are responsible for juvenile polyposis / HHT overlap syndrome, have been described7. ENG 
and ACVRL1 encode endothelial cell transmembrane proteins that appear to be components of 
the receptor complexes for growth factors of the Transforming Growth Factor-beta 
superfamily (TGF-beta). It has thus been hypothesized that HHT is related to an imbalanced 
state between anti-angiogenic factors and pro-angiogenic factors (such as VEGF)8. 
 Because of the molecular mechanisms involved in both angiogenesis and HHT, as 
well as the mechanisms of action of anti-VEGF such as bevacizumab, a prospective study has 
been performed using intravenous bevacizumab in severe hepatic forms of HHT and reported 
a significant improvement of liver consequences as well as epistaxis9.  To limit the systemic 
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adverse effects of bevacizumab and to ease administration, a local administration seemed 
suitable. We therefore investigated bevacizumab transport through porcine nasal mucosa to 
determine antibody bioavailability and we evidenced absorption of bevacizumab into nasal 
mucosa10. Furthermore, several published cases reported a potential efficacy of bevacizumab 
nasal spray11-16. 
Our aim was to evaluate safety of bevacizumab nasal spray. The secondary objectives were 
(1) to study systemic passage and pharmacokinetic of bevacizumab in blood after nasal spray 
delivery, (2) to evaluate efficacy on epistaxis (duration and number), on anemia 
(hemoglobinemia and ferritinemia) and on number of blood transfusions. 
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MATERIALS AND METHODS 
This trial was registered with the ClinicalTrials.gov Identifier #NCT01507480. Enrolment 
began in October 2011. 
Study design: Phase-1, randomized, double-blind, placebo-controlled, monocentric study 
carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group was made up 
of 6 verum and 2 placebos. Five increasing doses of bevacizumab nasal spray (25 mg/mL) 
were evaluated: 12.5, 25, 50, 75 and 100 mg. To escalate to a higher dose level, at least sixth 
of the eight patients of each dose level should have completed 14 days of follow-up with no 
dose-limiting toxicity. At each dose level a safety assessment was carried out by a scientific 
committee. Adverse events (AE) were classified as certainly, probably, possibly or dubitable. 
Dose-limiting toxicity was defined by any grade three and four toxicity events on the National 
Cancer Institute's common toxicity criteria scale (NCI-CTC version 4.0) with the exception of 
rest dyspnea, epistaxis, anemia associated with epistaxis or the chronic digestive hemorrhages 
associated with HHT before treatment. The sample size was based on previous pilot studies 
and was pragmatic with regard to determining toxicity-based dose escalation17. Thus, it was 
planned to randomize a minimum of 16 and a maximum of 64 patients by including 5 groups 
of 8 patients and, if necessary 3 additional groups of 8 patients in case of dose-limiting 
toxicity, justifying a double sample for the dose. 
Patients had a 3 months follow-up with visits at 14, 30 and 90 days after treatment including 
physical examination, laboratory testing (hemoglobinemia, ferritinemia), and assessment for 
adverse events. 
 
Patients’ selection 
This study enrolled patients older than 18 years old, with clinically confirmed HHT (the 
presence of at least three of the Curaçao criteria) suffering from epistaxis (more than 30 
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minutes a month as a mean over a three month-period assessed using specific grids filled by 
the patients). 
The main non-inclusion criteria were high blood pressure, presence of nasal septal perforation 
before treatment and previous bevacizumab treatment. Potentially eligible patients were 
identified during a 3 month-screening period. Compliance to treatment and ability to complete 
epistaxis grids were evaluated over this period. Patients were included chronologically by 
dose level. Within each dose level, randomization was performed for the allocation of verum 
or placebo. 
This study was approved by the local research ethics committee and by the French Medical 
Products Agency (AFSSAPS/ANSM). Oral and written informed consent were obtained from 
all patients in accordance with national regulations.  
 
Treatment 
Patients received a one day treatment of bevacizumab or placebo intranasally. Bevacizumab 
(Avastin® 25 mg/mL, Roche, Basel, Switzerland: bevacizumab, trehalose dihydrate, sodium 
phosphate, polysorbate 20, and water for injections) was not diluted and packaged by a 
pharmaceutical department in a calibrated nasal spray bottle which delivered 0.05 or 0.1 ml 
per nebulization according to the dose. Each patient received 1 to 4 nasal nebulization, 
according to the dose, administered every 30 minutes into each nostril for 2 hours during a 
one-day hospitalization period in a phase I/II unit. The placebo used was 0.9% sodium 
chloride. 
 
Outcome measures 
The main criterion was to evaluate safety at each visit by physical and nose examination, as 
well as laboratory testing, and assessment for adverse events. 
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Secondary evaluation criteria were: 
(1) Systemic passage and pharmacokinetic of bevacizumab. Its concentrations were measured 
in blood samples collected before treatment and, 2, 4, 6 and 24 hours after treatment. 
Bevacizumab serum concentrations were measured using a validated ELISA technique 18.   
(2) Daily epistaxis report using a grid to record daily duration and number of episodes. 
Hemoglobinemia, ferritinemia (laboratory testing) and number of blood transfusions were 
systematically recorded at each visit. 
 
Statistical analysis 
The efficacy population was defined by all randomized patients and the safety population by 
all treated patients. Quantitative parameters at inclusion were presented as mean ± standard 
deviation and median (minimum and maximum) for two groups (placebo group and 
bevacizumab group considered as a whole) and were compared using Student t-test (or Mann-
Whitney test in case of non-normality). Qualitative parameters at inclusion were presented in 
terms of number (percentage) and compared using chi-square test (or Fisher exact test where 
conditions for chi-square test were not fulfilled). 
For the analysis of safety, number of related and graded adverse event was counted for 
bevacizumab and placebo groups. For the analysis of secondary outcomes (efficacy criteria), 
monthly mean of number and duration of epistaxis (over a period of 3 months) and number of 
transfusions were compared before and after treatment using a Student’s test for dependant 
sample (or Wilcoxon signed rank test in case of non-normality). Differences between monthly 
mean of number and duration of epistaxis before and after treatment were compared between 
placebo group and bevacizumab group with Student t-test (or Mann-Whitney test in case of 
non-normality). Trend over time on haemoglobinemia and ferritinemia was assessed using a 
 8 
mixed model for repeated measures. All analyses were performed using SAS software version 
9.2 (SAS Institute Inc., Cary, NC, USA).  
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RESULTS 
Forty-two inclusions corresponding to forty-one patients occurred between October 2011 and 
October 2012. Forty patients were randomized (one patient was excluded due to an 
intercurrent pathology). One patient was included and randomized twice since he was 
excluded due to fever before treatment visit (non-inclusion criterion). After disappearance of 
this criterion, he was finally again included and randomized. Two patients were included 
whereas they had an old perforation of the nasal septum which was not detected at inclusion 
but after treatment. 
Finally, 40 patients (5 groups of 8 patients) received the treatment as indicated in the 
flowchart of the study (figure 1). 
No dose limiting toxicity was observed. Therefore, the the following dose levels were tested: 
12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg. 
 
Figure 1: Flowchart of the study 
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Patients’ characteristics before treatment (n=40) are summarized in table 1. Placebo and 
bevacizumab groups were similar except for monthly number of epistaxis. The mutated gene 
was ACVRL1 in 25 cases, ENG in 14 cases and not known in 1 cases. 
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Table 1: Patients’ characteristics before treatment 
Variable Expression Entire group 
n = 40 
Placebo group 
n = 10 
Treatment group 
n = 30 p-value 
Age (years) Mean ± SD 56.8 ± 10.2 57.9 ± 8.9 56.5 ± 10.7 0.93 
 Median  
(Min - Max) 
57.9  
(38.7 - 75.5) 
59.3  
(40.6 - 72.7) 
57.1  
(38.7 - 75.5) 
 
Females (%) n (%) 21 (52.5) 6 (60.0) 15 (50.0) 0.91 
Body mass index 
(kg/m²) 
Mean ± SD 
Median  
(Min - Max) 
25.7 ± 4.6 
24.5  
(19.0 - 37.5) 
24.9 ± 3.3 
24.8  
(20.3 - 30.7) 
26.0 ± 5.0 
24.5  
(19.0 - 37.5) 
0.94 
ENT surgery-  n (%) 15 (37.5) 4 (40.0) 11 (36.7) 1.00 
before treatment 
 
n (%) 
 
10 (25.0) 
 
3 (30.0) 
 
7 (23.3) 
 
0.88 Laser 
Biological glue n (%) 2 (5.0) 1 (10.0) 1 (3.3) 0.59 
aetoxysclerol n (%) 2 (5.0) 1 (10.0) 1 (3.3) 0.59 
Arterial embolisation n (%) 1 (2.5) 0 (0.0) 1 (3.3) 1.00 
Arterial surgery n (%) 1 (2.5) 0 (0.0) 1 (3.3) 1.00 
Other treatment n (%) 6 (15.0) 0 (0.0) 6 (20.0) 0.42 
Epistaxis/month  
    
 
Duration  
 
Mean ± SD  
Median  
(Min - Max) 
165.9 ± 110.5 
128.5  
(26 - 490) 
155.8 ± 112.9 
121.5  
(52 - 451) 
169.23± 111.4 
158.5  
(26 - 490) 0.94 
Number  Mean ± SD  
 
23.1 ± 14.5 
 
30.7 ± 15.2 
 
20.5 ± 13.5 0.07 
 
Median  
(Min - Max) 
20  
(5 - 62) 
26.5  
(13 - 58) 
18.5  
(5 - 62) 
 
Hemoglobinemia 
(g/L)  
Mean ± SD  
Median  
(Min - Max) 
122.0 ± 23.5 
125.5  
(72 - 161) 
122.0 ± 26.0 
132  
(75 - 155) 
122.0 ± 23.1 
124  
(72 - 161) 
0.98 
Ferritinemia (µg/l) Mean ± SD  
Median  
(Min - Max) 
34.7 ± 32.1 
26.5  
(1 - 171) 
23.8 ± 22.3 
13.5 
(1 - 72) 
38.4 ± 34.2 
29  
(1 - 171) 
0.24 
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Adverse effects 
No grade 3 and 4 certainly or probably related adverse events (AE) were recorded. Three 
grade 2 AE were considered as dubitable or possibly related (rhinopharyngitis (n=1), 
cephalgia (n=1), moderate blood hypertension (n=1)). Lastly, 8 grade 1 AE (nausea (n=1), 
vomiting (n=1), asthenia (n=1), erythemia (n=1), headache (n=4)) were registered among 30 
patients treated with bevacizumab .Three AE were observed among 10 patients from placebo 
group (headache (n=2) and skin rash (n = 1)). No related AE was observed among the 2 
patients with nasal septum perforation.  
Two unrelated serious AE were observed (anemia (n=1) and uterine surgery (n=1)) among 
patients treated with bevacizumab versus one unrelated serious AE among placebo group 
(retinal detachment (n = 1)).  
 
 
Bevacizumab pharmacokinetics 
Bevacizumab has not been detected in any blood samples whatever the sampling time. 
 
Efficacy on epistaxis is summarized in table 2 and figure 2. No significant difference was 
observed before and after treatment on epistaxis (number and duration) or blood transfusions 
between bevacizumab and placebo groups. Duration of epistaxis after treatment was also not 
significant between bevacizumab and placebo groups (p=0.628). 
There was no significant trend over time on ferritinemia and haemoglobinemia whatever the 
dose level (figure 2).  
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Table 2: Efficacy on epistaxis 
Variable  
Group 1 
12.5 mg 
n=6 
Group 2 
25 mg 
n=6 
Group 3 
50 mg 
n=6 
Group 4 
75 mg 
n=6 
Group 5 
100 mg 
n=6 
Placebo group 
n=10 
Epistaxis duration before 
treatment (min /month) 
Mean ± SD 79.22 ± 57.90 143.52 ± 93.55 214.12 ± 102.53 244.58 ± 157.09 177.82 ± 73.54 164.68 ± 123.73 
Median (Min - Max) 65.1 
(26.8 - 175.1) 
120.8 
(55 - 307.5) 
202.2 
(98.7 - 370.2) 
193.75 
(57.4 - 500.4) 
170.95 
(85 - 301.4) 
126.7 
(48.3 - 490.4) 
 
      
Epistaxis duration after 
treatment (min /month) 
Mean ± SD 77.12 ± 57.12 131.88 ± 136.77 274.68 ± 273.91 179.45 ± 117.02 187.70 ± 95.15 127.02 ± 68.10 
 Median (Min - Max) 52 
(28 - 167.9) 
107.8 
(18.9 - 393.5) 
177.25 
(102.9 - 830.3) 
189 
(39.6 - 372.5) 
214.2 
(19.9 - 276.3) 
151.15 
(13.3 - 202.4) 
p-value  0.89 0.64 0.68 0.10 0.76 0.11 
Epistaxis number before 
treatment (n /month) 
Mean ± SD 24.53 ± 15.95 19.67 ± 10.11 10.98 ± 6.02 23.45 ± 20.49 29.90 ± 17.95 29.99 ± 15.26 
 Median (Min - Max) 20.35 
(10.8 - 55.4) 
18.15 
(7.7 - 33.4) 
9.8 
(5.1 - 21.1) 
16.15 
(9 - 64.7) 
27.55 
(8.4 - 59.9) 
27.8 
(12.5 - 66.2) 
 
Epistaxis number after 
treatment (n /month) 
       
Mean ± SD 20.77 ± 10.20 17.45 ± 18.15 11.37 ± 6.02 24.82 ± 20.38 30.28 ± 17.98 26.75 ± 12.82 
Median (Min - Max) 16.7 
(10.1 - 37) 
11.55 
(3.7 - 52.8) 
9.9 
(6 - 21.9) 
17.35 
(10.4 - 64.1) 
24.75 
(10.1 - 58.2) 
25.8 
(3.3 - 43.5) 
p-value  0.29 0.74 0.11 0.68 0.91 0.45 
 
 
 
Figure 2: Efficacy on biological parameters (2a: Hemoglobine level before and after 
treatment, 2b: Ferritinemia before and after treatment)  
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DISCUSSION 
 This is the first prospective phase 1 clinical trial on bevacizumab nasal spray in HHT 
patients. Our results show that intranasal bevacizumab was very well tolerated immediately, 
30 and 90 days after a one day nasal spray administration, whatever the dose. Preclinical 
study previously suggested that bevacizumab was well tolerated by mucosa10, as did 
retrospective studies16. In the present study, no treatment-related adverse event was observed. 
Patients were carefully followed for nasal cartilaginous septum perforations which have been 
described as a side effect of intravenous bevacizumab in cancer patients19-22. This 
complication was also described after bevacizumab submucosal injection14,23 or laser 
treatment but never with topical treatment. In this study, nasal cartilaginous septum 
perforation was not observed following treatment administration. 
 No systemic absorption was evidenced. However, we cannot exclude that 
bevacizumab may be measured in serum after repeated nasal administration. Bevacizumab 
has a high molecular weight (149 kDa), a characteristic which should limit transport through 
biological membranes. However, FcRn, a receptor expressed on many epithelial surfaces 
including bronchial cells, may allow the transcellular transfer of IgG through the mucosa, 
although its presence in the nasal mucosa has not been reported. ex vivo studies showed that a 
large amount of the antibody was able to penetrate and cross the porcine nasal cavity 
mucosa10. The limit of detection of the ELISA technique used to measure bevacizumab serum 
concentrations was 0.033 mg/L18. Bevacizumab was used without dilution and it has been 
shown that the drug is very stable, even after storage, allowing a nasal spray use24. However, 
the nasal mucosa of HHT patients is very often damaged and we can hypothesize that nose 
bleeds, nasal crusts and dry nose modified local absorption of bevacizumab. In future studies, 
a moistening of nasal mucosa before treatment may be discussed.   
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 Nose bleeds are a major life threatening complication in HHT. A significant 
improvement of epistaxis after intravenous bevacizumab has been previously shown9, but, to 
decrease the risk of systemic adverse effects of the drug, intranasal administration was 
developed. In the present study, no significant improvement on epistaxis and on hemoglobinia 
was observed after a one-day administration whatever the dose. In the literature, several case 
reports and pilot studies reported a potential effect of bevacizumab nasal spray on epistaxis in 
HHT, with different doses and frequency of administration13-15,23,25. However, frequency of 
epistaxis is highly variable in a given patient and between patients and it is currently not 
possible to conclude on efficacy based on those reports. We can hypothesize that a one-day 
treatment is not enough to act on epistaxis. Furthermore, the calculation of the sample size 
was not designed for a phase 2 study and maybe more patients are needed to prove a 
significant effect on epistaxis duration. To date, 2 phase-II studies on bevacizumab nasal 
spray in HHT are registered in clinicaltrials.gov and are still recruiting (NCT01397695, 
NCT01408030). 
 
In conclusion, bevacizumab given by nasal spray as single dose is safe in HHT. A 
randomized phase 2 study is needed to assess the efficacy of this route of administration on 
epistaxis. Since we observed no difference between the doses tested, we cannot conclude on 
the most appropriate daily dose of bevacizumab which should be used in nasal spray. 
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